A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00367445
First received: August 21, 2006
Last updated: January 25, 2008
Last verified: January 2008

August 21, 2006
January 25, 2008
September 2006
Not Provided
Variability of blood glucose over a period of 72 hours
Same as current
Complete list of historical versions of study NCT00367445 on ClinicalTrials.gov Archive Site
Insulin pharmacokinetics
Same as current
Not Provided
Not Provided
 
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Inhaled Human Insulin (Exubera)
  • Drug: Insulin Glargine (Lantus)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2007
Not Provided

Inclusion Criteria:

  • Diabetes mellitus Type 2

Exclusion Criteria:

  • Severe Asthma, severe COPD
  • Smoking
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00367445
A2171094
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP